Trials / Conditions / Endometrial Transitional Cell Carcinoma
Endometrial Transitional Cell Carcinoma
5 registered clinical trials studyying Endometrial Transitional Cell Carcinoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01642082 | Gynecologic Oncology Group | Phase 2 |
| Completed | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01225887 | Gynecologic Oncology Group | Phase 2 |
| Completed | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer NCT01440998 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00888173 | Gynecologic Oncology Group | Phase 2 |